It’s barely a month since Merck & Co unveiled trial results showing that cancer immunotherapy Keytruda (pembrolizumab) works in colorectal cancer patients with certain mutations, and the FDA ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

Keytruda was approved in 2017 in previously treated MSI-High or dMMR solid tumours, the first time a cancer therapy was licensed by the FDA for use on a biomarker, regardless of tumour type. Image ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Cancer drug dealmaking is heating up around ... addressed by the pharmaceutical giant’s blockbuster immunotherapy, Keytruda. Now Merck is joining in with a $588 million deal of its own.

Merck & Co. said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its blockbuster cancer drug Keytruda in certain patients with a ...

The cancer immunotherapy Keytruda, which is Merck’s most important product and the best-selling drug in the world with $23 billion in annual sales, is set to lose patent protection and face ...

BioNTech adds bispecific candidate, mRNA delivery startup as cancer work takes center stage The opportunity is enormous: Keytruda alone generated $25 billion last year across multiple indications.

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

Keytruda (pembrolizumab) is a brand-name solution for IV infusion prescribed to treat many types of cancer, including melanoma and lung cancer. As with other drugs, Keytruda can cause side effects ...

Phase 1a dose escalation for CX-904 (EGFR-CD3 PROBODY® T-cell engager) continues to advance. Potential Phase 1b initiation in 2025. -- Phase 1 ...